Patient Engagement Study for Participants with Dyslipidemia
Research type
Research Study
Full title
A patient engagement study to inform adult participants with refractory dyslipidemias about CRISPR gene-editing trials, familiarise them with the Clinical Trials Unit environment and establish their eligibility and participation.
IRAS ID
352361
Contact name
Jorg Taubel
Contact email
Sponsor organisation
CRISPR Therapeutics AG
Duration of Study in the UK
1 years, 9 months, days
Research summary
Dyslipidemia is a condition where there are unhealthy levels of fats in the blood. When these levels stay high, even with treatment, it is called uncontrolled hyperlipidemia. This condition is a common problem that can lead to heart disease and other health issues if not managed properly.
A patient engagement study is being carried out to provide participants with Dyslipidemias the opportunity to become familiar with the clinical trials unit environment and study team before deciding if they want to take part in future gene editing clinical trials for their disease.
The study involves an in-person visit to the study unit on Day 1. During this visit, participants will receive a tour of the unit and undergo a series of clinical tests and procedures to assess their health. A follow-up phone call with a study doctor will be scheduled for one week after Day 1 (Day 7) to discuss the results of the clinical investigations and allow participants to ask any questions. Following this, participants will have follow-up calls every 12 weeks with the study doctor. If there are any significant changes in their health, they may be invited to attend the unit for an optional in-person visit.
REC name
London - Brent Research Ethics Committee
REC reference
25/PR/0134
Date of REC Opinion
12 Mar 2025
REC opinion
Favourable Opinion